JSE Close: AB InBev Surges 8.3%, Aspen Insulin Approval Lifts Pharma

South African markets closed moderately positive on Tuesday, 5 May 2026, with the All Share rising 0.31% as sector dispersion widened sharply. The resource-heavy counters provided lift, with the FTSE/JSE Energy index gaining 2.74% and Precious Metals & Mining adding 0.72%, while financials lagged as the SA Banks index dipped 0.20%. AB InBev was the session's standout performer, surging 8.26% to R1345.67 after reporting strong first-quarter earnings, while Aspen Pharmacare climbed 5.61% on news that its locally manufactured human insulin had received commercial approval from SAHPRA. The FTSE/JSE Beverages index logged an extraordinary 8.26% gain, reflecting AB InBev's outsized influence on the sub-sector weighting, while Health Care broadly outperformed with a 3.19% advance.

ANH AB InBev Posts 20.8% EPS Growth, Premium Segments Drive Q1 Beat

AB InBev delivered a robust first quarter on Tuesday, reporting a 20.8% increase in Underlying EPS to 0.97 USD and a 5.8% rise in total revenue, sending the JSE's largest index constituent sharply higher. The brewer's premium and beyond-alcohol categories were the primary growth engines, with no-alcohol beer expanding 27% and Beyond Beer surging 37%, reflecting the company's ongoing portfolio diversification strategy. The BEES Marketplace also continued rapid scaling, posting a 55% increase in Gross Merchandise Value to 1.1 billion USD, underscoring the growing contribution from its technology-enabled distributor ecosystem. Management reaffirmed its medium-term EBITDA growth outlook of 4–8%, providing stable forward guidance even as the normalised EBITDA margin contracted by 15 basis points to 35.6%, a modest headwind that investors appeared willing to overlook given the top-line momentum.

The share surged 8.26% to close at R1345.67, contributing disproportionately to the FTSE/JSE Beverages index's extraordinary 8.26% one-day gain, and also supported the broader Top 40 and Industrial indices. While the stock trades at a demanding trailing P/E of 22.4x and carries net capital expenditure guidance of up to 4.0 billion USD alongside a 4% average gross debt coupon, the Q1 results validate the core thesis that diversification into premium and no-alcohol segments provides resilience against domestic consumer spending pressure. The company separately updated investors on its ongoing share buy-back programme, having cumulatively repurchased 1.01% of total shares outstanding for over 1.2 billion EUR since November 2025, representing a mechanical EPS-accretive mechanism that continues to support per-share metrics.

APN Aspen Secures SAHPRA Nod for Locally Manufactured Human Insulin

Aspen Pharmacare received regulatory clearance from the South African Health Products Regulatory Authority to commence commercial sales of locally manufactured human insulin from its Gqeberha sterile manufacturing facility, the company announced on Tuesday. The commercial launch transitions a previously announced contract manufacturing agreement into active revenue generation, validating Aspen's execution capabilities in sterile finished-dose form manufacturing at the facility. The product addresses a high-volume chronic disease market, with diabetes prevalence in South Africa representing a growing healthcare burden and an attendant opportunity for locally sourced pharmaceutical supply. The stock rose 5.61% to close at R148.04, contributing to the FTSE/JSE Pharmaceuticals & Biotechnology index's standout 5.61% gain for the session.

The insulin approval is meaningful as a thesis confirmation for Aspen's manufacturing strategy, though the broader group still faces execution requirements given its negative trailing EPS of R-0.04. The Gqeberha facility's progression from development-stage investment to commercial revenue stream derisks the manufacturing segment's near-term outlook. Separately on Tuesday, Aspen disclosed routine director and prescribed officer dealings under its 2016 Long-term Retention Share Scheme, in which CEO Sean Matthew Capazorio and Prescribed Officer Lorraine Angela Hill each received share scheme awards of approximately R7.6 million and subsequently sold shares worth R3.55 million on-market solely to settle tax obligations on the vesting. Both individuals retained the majority of their vested allocations, indicating continued alignment with shareholder interests, and this administrative filing carries no signal regarding insider conviction in the company's earnings trajectory.

MCZ MC Mining Secures US$90M KDG Funding, Cedes Control to New Majority Shareholder

MC Mining confirmed the completion of its US$90 million capital injection from Kinetic Development Group on Tuesday, with the final allotment of 28.8 million shares establishing KDG as a 51% controlling shareholder. The definitive funding closure removes the balance sheet risk that has constrained development of the Makhado Project, which targets total production capacity of 1.5 million tonnes per annum, comprising 800,000 tonnes of hard coking coal and 700,000 tonnes of thermal coal. The company has simultaneously announced board changes, accepting the resignation of a non-executive director and appointing two KDG nominees, formalising the governance transition to a controlled-subsidiary structure under the new majority shareholder's oversight. Bill Pavlovski remains as Company Secretary, preserving institutional memory during the transition.

The funding completion is a material derisking event for the Makhado Project's development pathway, but minority shareholders must now accept subsidiary status under KDG's majority control, fundamentally altering the strategic influence available to existing investors. The production capacity targets remain forward-looking assumptions subject to operational execution risk in construction and ramp-up. The announcement carried no immediate price catalyst, with the stock having likely priced in the long-anticipated milestone following its substantial recovery from its 52-week low. The corporate governance restructuring under KDG's nominees represents a permanent shift in the minority investment case, moving from a standalone development story to a subsidiary play under an experienced global coal operator.

MTM Momentum Group Restructures Board Committees Following New Chair Appointment

Momentum Group announced routine board committee changes on Tuesday, redistributing oversight responsibilities following the appointment of Tyrone Soondarjee as Group Chair. Linda de Beer has assumed the chairmanship of both the Audit Committee and the Remuneration Committee, succeeding the prior chair who vacated the role in the leadership transition. Experienced non-executive directors including Ann Frances Leautier will remain on key committees, providing continuity of governance expertise. The restructuring is designed to balance director workloads in an orderly fashion and does not reflect any change in corporate strategy, operational direction, or the financial trajectory of Momentum's insurance and investment operations. The stock declined 2.26% alongside the announcement, though this move appeared to reflect broader market dynamics rather than any direct equity implication from the governance update.

The committee reshuffle concentrates significant oversight responsibility on a single director, which some institutional investors may view as a bandwidth consideration, but the move is grounded in the appointment of a highly experienced incumbent rather than a compromise in governance quality. Momentum Group's filings explicitly characterise this as a mechanical governance event with no implications for the equity thesis or valuation framework. Investors monitoring the insurance and wealth management group's broader fundamentals should look to scheduled results releases for material trading updates rather than this administrative filing.

NED Nedbank COO Realises R10.4 Million Following Incentive Scheme Vesting

Nedbank Group disclosed on Tuesday that Chief Operating Officer MC Nkuhlu had sold 39,221 shares on-market for approximately R10.4 million, following the vesting of awards under the Nedbank Group 2005 Restricted Share Plan and the 2023 Matched Share Scheme. The transaction was executed with formal governance clearance and reflects standard executive remuneration mechanics, in which long-term incentive awards mature and employees sell a portion of vested holdings to settle associated tax obligations. The sale represents a routine liquidity event rather than a discretionary exit reflecting any change in the executive's view of Nedbank's earnings outlook or dividend prospects. The disclosure aligns with standard JSE Listings Requirements for dealings in securities by persons discharging managerial responsibilities.

The COO's share sale carries no signal regarding insider conviction in Nedbank's financial performance, as the transaction was explicitly triggered by scheme vesting mechanics rather than a discretionary open-market trade. Nedbank's shares were marginally negative on the session, in line with the broader financial sector weakness that saw the SA Banks index decline 0.20% and the Financials & Industrials index add only 0.10%. The FTSE/JSE Finance & Credit Services index was notably weak, falling 2.21%, reflecting sector-specific headwinds rather than company-specific news flow. Investors focused on Nedbank's fundamentals should monitor for scheduled results announcements and any regulatory decisions affecting the banking sector's net interest margin outlook.

What we are watching

Wednesday, 13 May 2026, brings Karooooo's scheduled Q4 and full-year 2026 financial results release, with the fleet management and data analytics group expected to report against a backdrop of 125,000 commercial customers and 2.7 million active subscribers. Burstone Group has separately confirmed it will release its FY26 annual financial results on 2 June 2026. Both filings may provide directional cues for their respective sectors, with Karooooo's results arriving amid a demanding trailing price-to-book multiple of 8.01x that leaves limited margin for error in the disclosed figures.